Voyager Therapeutics Inc. Stock Analysis VYGR

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Lexington, Massachusetts and currently employs 141 full-time employees. The company went IPO on 2015-11-11. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.